IMPORTANT POINTS:
- Nine healthcare stocks have doubled in value by 2024 and still have more than 100% growth potential, according to analysts.
- Companies such as Jasper Therapeutics, Corbus Pharmaceuticals and Rezolute are leading the growth, with expectations for significant increases in the next 12 months.
- These biotech stocks present high risk, but also high reward opportunities for investors seeking high returns.
Nine healthcare stocks have doubled their value in 2024, but could still continue to grow more than 100%, according to several analysts.
An analysis by CNBC Pro reviewed more than 85,000 global companies to identify those that have increased their value by at least 100% this year. All of these stocks are covered by five or more analysts, who predict that they will continue to grow at a similar rate over the next 12 months.
Notable companies on Nasdaq include: Jasper Therapeutics, Corbus Pharmaceuticals, Rezolute, Trevi Therapeutics, Delcath Systems, Benitec Biopharma, Arcutis Biotherapeutics, Praxis Precision Medicines and Humacyte.
The biotechnology sector is known for its high risk, but also for its potential to generate high profits.
Companies with great performance in 2024 and more to come
| Symbol | Name | Increase in 2024 (%) | Growth potential (%) | Analysts |
|---|---|---|---|---|
| JSPR | Jasper Therapeutics | 131.7 | 277.5 | 11 |
| CRBP | Corbus Pharmaceuticals | 212.4 | 252.4 | 8 |
| RZLT | Rezolute | 385.6 | 180.1 | 8 |
| TRVI | Trevi Therapeutics | 137.3 | 151.6 | 10 |
| DCTH | Delcath Systems | 114.7 | 140.8 | 6 |
| BNTC | Benitec Biopharma | 203.7 | 103.9 | 5 |
| ARQT | Arcutis Biotherapeutics | 189.5 | 103.2 | 7 |
| PRAX | Praxis Precision Medicines | 223.4 | 102.6 | 10 |
| HUMA | Humacyte | 100.7 | 101.8 | 6 |
Source: FactSet, CNBC Pro
Jasper Therapeutics: At the forefront of growth
Jasper Therapeutics is a biotech company focused on developing briquilimab, a drug that could treat conditions related to stem cells and mast cells, such as skin rashes and asthma. Currently, 11 Wall Street firms cover its shares, and all agree that the price could more than double in the next 12 months. The average price target is $69, representing potential growth of 278%.
Corbus Pharmaceuticals: Innovative cancer treatments
Corbus Pharmaceuticals, founded in 2009, specializes in the development of new cancer treatments. The Massachusetts-based company is also researching potential treatments for obesity. Eight analysts project an average price target of $66.50, meaning an expected growth of 252% in the coming year.
Rezolute: Focus on rare diseases
Rezolute, founded in 2010, works on treatments for rare diseases, with a special focus on low blood sugar problems. Despite being up 385% in 2024, analysts believe the company has an additional 180% growth potential over the next 12 months.
Trevi Therapeutics: Innovation for chronic cough
Trevi Therapeutics is developing Haduvio, a treatment for chronic cough associated with some lung diseases. Chronic cough affects 10% of the population in the United States, and can worsen certain respiratory conditions. There are currently no approved treatments for this condition, giving Trevi great market potential. Analysts predict growth of 152% for the next 12 months.
Delcath Systems: Advances in the treatment of liver cancer
Delcath Systems, founded in 1988, specializes in the treatment of liver cancer. It already has approved treatments in both the United States and Europe. Despite having doubled its value this year, analysts estimate that it could grow another 140% in the coming months.
Benitec Biopharma: Genetic therapies with high potential
Benitec Biopharma, founded in Australia in 1995, focuses on developing gene therapies for various diseases. Based in California, its shares are expected to rise 104% over the next 12 months, after rising 203% so far in 2024.
Arcutis Biotherapeutics: Innovative dermatological solutions
Arcutis, founded in 2016, has managed to bring three dermatological products to the market with FDA approval. Its share value is expected to rise 103% in the next 12 months, after growing 190% this year.
Praxis Precision Medicines: Treatments for the brain and nervous system
Praxis Precision Medicines is dedicated to developing therapies for disorders of the brain and nervous system. Its shares have risen 223% in 2024, and are expected to continue rising 103% in the coming year, according to the 10 analysts covering the company.
Humacyte: Pioneers in artificial organs
Humacyte is developing artificial tissues and organs that could be implanted universally. The company has doubled in value this year, and analysts expect it to double again in the next 12 months.
Finally, these companies have demonstrated impressive growth in 2024, and analysts suggest they still have a long way to go. Therefore, investors looking for high-risk, high-reward opportunities could find these stocks an excellent option.
Descargo de responsabilidad: Toda la información encontrada en Bitfinanzas es dada con la mejor intención, esta no representa ninguna recomendación de inversión y es solo para fines informativos. Recuerda hacer siempre tu propia investigación.